Author

Gil Y. Melmed 1

1 Cedars-Sinai Medical Center,Los Angeles,United States

EFFICACY OF VEDOLIZUMAB WITH AND WITHOUT CONTINUED IMMUNOSUPPRESSANT USE IN GEMINI 1 AND GEMINI 2

Brian G. Feagan, Corey A Siegel, Gil Y. Melmed, Kim Isaacs, Karen Lasch, Maria Rosario, Alexandra Green, Brihad Abhyankar

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019

Kevin L. Winthrop, Gil Y. Melmed, Severine Vermeire, Nervin Lawendy, Rajiv Mundayat, nicole kulisek, Chinyu Su

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES

Kevin L. Winthrop, Severine Vermeire, Julian Panés, Gil Y. Melmed, nicole kulisek, Rajiv Mundayat, Nervin Lawendy, Chinyu Su

IMPACT OF CONCOMITANT IMMUNOMODULATOR TREATMENT ON EFFICACY AND SAFETY OF ANTI-TNF THERAPY IN CROHN’S DISEASE: A META-ANALYSIS OF PLACEBO CONTROLLED TRIALS WITH INDIVIDUAL PATIENT-LEVEL DATA

Jennifer Jones, Laurent Peyrin-Biroulet, L Baidoo, Shane Devlin, Gil Y. Melmed, D Tanyingoh, L Raffals, Peter Irving, Patricia Kozuch, Miles P. Sparrow, Fernando Velayos, Brian Bressler, A Cheifetz, Jean-Frederic Colombel, Corey A Siegel, Gilaad G. Kaplan

Internally Applied Ultraviolet Light as A Novel Approach for Effective and Safe Anti-Microbial Treatment

Ali Rezaie, Gabriela Leite, Jaeho Park, Seungyoung Kim, Stacy Weisman, Gil Y. Melmed, Gillian Barlow, Walter Morales, Shreya Celly, Gonzalo Parodi, Siamak Sakhaie, Zev Melmed, Enrique Ybarra, Ruchi Mathur, Mark Pimentel

Laboratory parameters related to monitoring in patients with ulcerative colitis treated with tofacitinib for up to 3 years in the OCTAVE open-label, long-term extension study

Gil Y. Melmed, Shannon Chang, nicole kulisek, Haiyun Fan, Nervin Lawendy, Eric Maller, Arif Soonasra, Peter Irving

Takeda - Shared Decision-making in Ulcerative Colitis: Balancing Benefits and Risks to Optimise Outcomes (Takeda Pharmaceuticals International AG)

Geert R. D'Haens, Gil Y. Melmed, Benjamin Pariente

THE APPROPRIATENESS OF TESTING AND INTERPRETATION OF ANTI-TNF DRUG AND ANTIBODY CONCENTRATIONS: WHEN SHOULD THEY BE ORDERED, AND WHAT TO DO WITH THE RESULTS?

Gil Y. Melmed, Peter Irving, Gilaad G. Kaplan, Brian Bressler, Jennifer Jones, Patricia Kozuch, Miles P. Sparrow, Fernando Velayos, Leonard Baidoo, Adam Cheifetz, Shane Devlin, Laura Raffals, Niels Casteele, Diane R. Mould, William Sandborn, Corey A Siegel

UPDATE ON LABORATORY PARAMETERS RELATED TO MONITORING IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY

Gil Y. Melmed, Shannon Chang, nicole kulisek, Kenneth Kwok, Nervin Lawendy, Peter Irving

Item 1 - 9 / 12
1
2